Can-Fite CSO reports option holdings
Can-Fite BioPharma Ltd. director and Chief Scientific Officer Pnina Fishman reported her initial holdings on a Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Can-Fite BioPharma Ltd. director and Chief Scientific Officer Pnina Fishman reported her initial holdings on a Form 3. She directly holds several option grants to purchase Ordinary Shares with exercise prices ranging from USD 17.39 to USD 2,264.01, plus 88 Ordinary Shares. Some options are fully vested and exercisable, while others continue vesting in quarterly installments through dates extending to June 30, 2029, subject to her continued service.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Fishman Pnina
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Options to Purchase Ordinary Shares — 10,299 contracts (Direct);
Ordinary Shares — 88 shares (Direct)
Footnotes (9)
- F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
- F2. These options are fully vested and exercisable as of the date hereof.
- F3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 7,032, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
- F4. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in UUSD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
- F5. The exercise price of this option, originally denominated in NIS in the amount of NIS 768.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
- F6. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 857 options are vested, and the remaining 125 options vest in two equal quarterly installments beginning 04/17/2026 and ending 07/17/2026 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
- F7. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,718 options are vested, and the remaining 782 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
- F8. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,093 options are vested, and the remaining 1,407 options vest in nine equal quarterly installments beginning 07/03/2026 and ending 07/03/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
- F9. The exercise price of this option, originally denominated in NIS in the amount of NIS 54, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 156 options are vested, and the remaining 2,344 options vest in fifteen equal quarterly installments beginning 12/30/2025 and ending 06/30/2029 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Pnina Fishman’s Form 3 for Can-Fite BioPharma (CANF) show?
The Form 3 shows Pnina Fishman’s initial holdings as a director and Chief Scientific Officer, including multiple option grants to purchase Ordinary Shares and 88 directly held Ordinary Shares, with detailed exercise prices and vesting schedules extending to 2029.
What types of securities does Pnina Fishman hold in Can-Fite BioPharma (CANF)?
Pnina Fishman holds options to purchase Ordinary Shares plus 88 Ordinary Shares directly. The options have specified exercise prices in U.S. dollars and defined expiration dates, reflecting her equity-based compensation as an executive and director of Can-Fite BioPharma.
How are Pnina Fishman’s Can-Fite BioPharma (CANF) options vested?
Some options are fully vested and exercisable, while others vest in quarterly installments through dates as late as June 30, 2029. Vesting is conditioned on her continued service to Can-Fite BioPharma on each relevant vesting date, as described in the footnotes.
What are the exercise prices of Pnina Fishman’s options in Can-Fite BioPharma (CANF)?
The options’ exercise prices are originally denominated in New Israeli Shekels and presented in U.S. dollars. They range from about USD 17.39 per share to USD 2,264.01 per share, based on a Bank of Israel exchange rate from March 11, 2026.
Why are Can-Fite BioPharma (CANF) options held through a trustee under Section 102?
To qualify for certain Israeli tax benefits under Section 102, securities granted under Can-Fite BioPharma’s share option plans must be registered in the name of a trustee. This structure helps employees, including Pnina Fishman, receive favorable tax treatment on equity compensation.
Do Pnina Fishman’s Can-Fite BioPharma (CANF) Form 3 entries show any recent trades?
The entries are characterized as holdings rather than new purchases or sales. They detail existing option grants and Ordinary Share holdings, including vesting and expiration terms, rather than reporting fresh open-market transactions or exercises on the Form 3 date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
